Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs at Femasys Inc., has acquired 3,125 shares of the company's common stock for $10,000. The purchase, made on August 7, 2026, was at a price of $3.20 per share. This transaction is notable as the stock is currently trading near its 52-week low of $2.29, with a current price of $2.35. According to the securities purchase agreement, Mr. Mifek directly holds 3,125 shares of common stock following this transaction. In addition to the common stock, Mr. Mifek also acquired two common stock purchase warrants, each allowing for the acquisition of 3,125 shares at an exercise price of $2.95 per share.
Recent Developments
Femasys Inc. has recently regained compliance with Nasdaq's minimum bid price requirement and received CE Mark approval for its FemHSG Catheter, expanding its product portfolio in Europe. The FemHSG Catheter is designed to work with the company's FemVue device for ultrasound-based assessments.
